NYSE:BIOLife Sciences
What Bio-Rad Laboratories (BIO)'s Activist Pressure and Sartorius Stake Review Means For Shareholders
In recent months, Bio-Rad Laboratories attracted activist investor Elliott, prompting management to refine its acquisition approach, reassess research spending, and consider selling its multi-billion-dollar Sartorius stake to unlock capital for higher-return uses.
This shift signals a potentially more disciplined capital allocation framework, with activism acting as a catalyst for sharpening Bio-Rad’s focus on cash-generating businesses in Life Science and Clinical Diagnostics.
Next, we’ll...